Oncology

Redefining the treatment paradigm to eliminate cancer as a cause of death


Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.

At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.




Our scientific platforms

We've decided to concentrate on four scientific platforms that we believe give us the best chance in finding routes to effective medicines in the most efficient way.


Immuno-oncology

Using the body's immune system to help fight cancer


  • Tumour drivers and resistance

    Developing therapies that target specific mutations to attack cancer cells


    Watch video
  • DNA damage response

    Targeting the DNA repair process to block tumour cells' ability to reproduce


  • Antibody-drug conjugates

    Arming antibodies with cancer-killing agents for specific tumour targeting


    Watch video


Four key disease areas

There are many types of cancer disease. For us to be most effective, we've chosen to concentrate on four key diseases.





What we're working on

As part of our commitment to oncology, we're constantly working on new and exciting streams of work. Here are just a few of what we're up to at the moment.



Collaboration in Oncology

To eradicate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.





Commitment to science

Our commitment to science is reflected in our track record of publications. View recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Our Oncology pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Oncology (as at 27 April 2017)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD4635 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD9150 haematological malignancies
  • AZD9496 ER+ breast cancer
  • Lynparza + AZD1775 solid tumours
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3726 prostate cancer
  • MEDI4276 solid tumours
  • MEDI5083 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • durvalumab + AZD1775 solid tumours
  • durvalumab + Iressa NSCLC
  • durvalumab + MEDI0562 solid tumours
  • durvalumab + MEDI9447 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + monalizumab solid tumours
  • durvalumab + selumetinib solid tumours
  • durvalumab + tremelimumab solid tumours
  • durvalumab or durvalumab + (tremelimumab or AZD9150) diffuse large B-cell lymphoma
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • AZD1775 solid tumours
  • AZD1775 + chemotherapy ovarian cancer
  • AZD4547 solid tumours
  • AZD5363 breast cancer
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + cediranib CONCERTO recurrent platinum resistant ovarian cancer
  • MEDI-573 metastatic breast cancer
  • Tagrisso BLOOM CNS metastases in advanced EGFRm NSCLC
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + AZD5069 durvalumab + AZD9150 HNSCC
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + tremelimumab hepatocellular carcinoma (liver cancer)
  • durvalumab + tremelimumab gastric cancer
  • savolitinib/ volitinib papillary renal cell carcinoma
  • vistusertib solid tumours

Phase 3

Phase 3

  • acalabrutinib B-cell malignancy
  • acalabrutinib 1st line CLL
  • acalabrutinib r/r CLL, high risk
  • durvalumab ≥2nd-line advanced bladder cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab PEARL 1st-line NSCLC
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CASPIAN 1st-line SCLC
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • selumetinib ASTRA differentiated thyroid cancer

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm NSCLC
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm NSCLC

Our Oncology medicines

AstraZeneca’s medicines are effective and wide-ranging, using various combination therapies to create excellent drugs.


  • Arimidex anastrozole
  • Casodex, Cosudex bicalutamide
  • Faslodex fulvestrant
  • Iressa gefitinib
  • Lynparza olaparib
  • Nolvadex, Istubal, Valodex tamoxifen citrate
  • Tagrisso osimertinib
  • Zoladex goserelin acetate implant

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.



Veeva ID: Z4-4977
Date of next review: May 2018